Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 3/20 | 0.34 |
| ▸ | DRD3 | P35462 | 3/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.34 |
| ▸ | DRD1 | P21728 | 2/20 | 0.34 |
| ▸ | DRD4 | P21917 | 2/20 | 0.34 |
| ▸ | DRD5 | P21918 | 2/20 | 0.34 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7598091 | 0.90 | KMT2A (0.36) | KMT2AMEN1CES1HSD11B1SLC22A12 | |
| SCHEMBL2460558 | 0.85 | HSD11B1 (0.39) | HSD11B1DRD2DRD3DRD1DRD4 | |
| SCHEMBL15453749 | 0.80 | KMT2A (0.37) | KMT2AMEN1CES1HSD11B1SLC22A12 | |
| SCHEMBL6207099 | 0.78 | PPARG (0.43) | KMT2AMEN1DRD2DRD3SLC22A12 | |
| SCHEMBL15765824 | 0.78 | KMT2A (0.36) | KMT2AMEN1CES1SLC22A12ALDH1A1 | |
| SCHEMBL7601041 | 0.78 | DRD2 (0.39) | DRD2DRD3SLC22A12DRD1DRD4 | |
| SCHEMBL66020 | 0.78 | DRD2 (0.40) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL15453939 | 0.77 | CTSS (0.38) | KMT2AMEN1CES1GAA | |
| Iodide SCHEMBL7773907 | 0.77 | PPARG (0.42) | KMT2AMEN1DRD2DRD3SLC22A12 | |
| SCHEMBL3082218 | 0.77 | MRGPRX4 (0.46) | DRD2DRD3DRD4HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020042541-A1 | Process for producing bis( trifluoromethyl)benzaldehyde | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042541-A1 | Process for producing bis( trifluoromethyl)benzaldehyde | BRPF1, PFAS, FLI1 | KMT2A 2367/4885MEN1 639/4885CES1 2395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.